2024-03-31 10:00:00 ET
Summary
- Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion.
- Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation.
- Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate